Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Application for clinical trial of recombinant respiratory syncytial virus vaccine (CHO cells) accepted.

16:22 17/12/2025

Wan Tai Biology (603392.SH) announced that its wholly-owned subsidiary Xiamen Wan Tai Canghai Biotechnology Co., Ltd. has received the administrative licensing document "Acceptance Notice" from the National Medical Products Administration (referred to as the "NMPA"). The clinical trial application for the "Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)" submitted by the company has been accepted.

Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received an administrative license document from the National Medical Products Administration (referred to as the "NMPA") titled "Notice of Acceptance", indicating that the company's application for clinical trials of the "Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)" has been accepted.

CONSUN PHARMA (01681) spent 2.6422 million Hong Kong dollars on repurchasing 178,000 shares on December 17th.

Shenzhen Kangtai Biological Products (300601.SZ): Recombinant Hepatitis B Vaccine (Brewer's Yeast) (60g) added a new clinical trial approval for the new target population project.

TECHTRONIC IND (00669) spent 44.91 million Hong Kong dollars on December 17th to repurchase 500,000 shares.

CONSUN PHARMA (01681) spent 2.6422 million Hong Kong dollars on repurchasing 178,000 shares on December 17th.

Shenzhen Kangtai Biological Products (300601.SZ): Recombinant Hepatitis B Vaccine (Brewer's Yeast) (60g) added a new clinical trial approval for the new target population project.

TECHTRONIC IND (00669) spent 44.91 million Hong Kong dollars on December 17th to repurchase 500,000 shares.